| Dr Albert Siu, MD | |
|
526 Bloomfield Ave, Suite 104, Caldwell, NJ 07006-5564 | |
| (973) 226-0500 | |
| (973) 226-7221 |
| Full Name | Dr Albert Siu |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 19 Years |
| Location | 526 Bloomfield Ave, Caldwell, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063668895 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA08434200 (New Jersey) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 25MA08434200 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holy Name Medical Center | Teaneck, NJ | Hospital |
| Entity Name | Excelcare Medical Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992736300 PECOS PAC ID: 4284647868 Enrollment ID: O20060727000044 |
News Archive
Everyday products carry environmental chemicals that may be making us fat by interfering with our hormones, according to research presented in Barcelona at the European Society of Endocrinology annual meeting, ECE 2018.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
Although "repeal and replace" has been the Republican position on Obamacare since 2010, "replace" has been there mainly because it polled well. Republicans were satisfied with the health-care status quo in 2009, and would have been glad to repeal Obamacare to return to it. As Steve Benen points out, Republicans voted for just-plain-repeal many times.
Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.
Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.
› Verified 4 days ago
| Entity Name | Center For Nephrology & Hypertension |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013295286 PECOS PAC ID: 1951571959 Enrollment ID: O20110831000031 |
News Archive
Everyday products carry environmental chemicals that may be making us fat by interfering with our hormones, according to research presented in Barcelona at the European Society of Endocrinology annual meeting, ECE 2018.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
Although "repeal and replace" has been the Republican position on Obamacare since 2010, "replace" has been there mainly because it polled well. Republicans were satisfied with the health-care status quo in 2009, and would have been glad to repeal Obamacare to return to it. As Steve Benen points out, Republicans voted for just-plain-repeal many times.
Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.
Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Albert Siu, MD 526 Bloomfield Ave, Suite 104, Caldwell, NJ 07006-5564 Ph: (973) 226-0500 | Dr Albert Siu, MD 526 Bloomfield Ave, Suite 104, Caldwell, NJ 07006-5564 Ph: (973) 226-0500 |
News Archive
Everyday products carry environmental chemicals that may be making us fat by interfering with our hormones, according to research presented in Barcelona at the European Society of Endocrinology annual meeting, ECE 2018.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
Although "repeal and replace" has been the Republican position on Obamacare since 2010, "replace" has been there mainly because it polled well. Republicans were satisfied with the health-care status quo in 2009, and would have been glad to repeal Obamacare to return to it. As Steve Benen points out, Republicans voted for just-plain-repeal many times.
Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.
Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.
› Verified 4 days ago
Giovanni Campanile, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 14 Smull Ave, Caldwell, NJ 07006 Phone: 862-260-3188 Fax: 973-401-2489 | |
Dr. Stanley Mayrowetz, MD Nephrology Medicare: Medicare Enrolled Practice Location: 8 Brookside Ave, Caldwell, NJ 07006 Phone: 973-228-3333 Fax: 973-228-9023 | |
Michael Sidney Horowitz, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 112 Bloomfield Ave, Caldwell, NJ 07006 Phone: 973-364-1444 Fax: 973-364-0101 | |
Dr. Joel Notkin, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 526 Bloomfield Ave, Caldwell, NJ 07006 Phone: 973-226-0500 Fax: 973-226-7221 | |
Dr. Lynette G Suarez, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 360 Bloomfield Ave, Caldwell, NJ 07006 Phone: 973-226-8464 Fax: 973-226-3750 | |
Edwin Suarez, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 360 Bloomfield Ave, Caldwell, NJ 07006 Phone: 973-226-0722 Fax: 973-226-3750 |